Nadine Dufeu

Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia

Justine Frija‐Masson, Laurence Bassinet, Isabelle Honoré et al. · Thorax · 2016 · 108 citations · Full text

Medicine, Clinical Sciences, Pathology +14

Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease

D. Hubert, R. Chiron, B. Camara et al. · Journal of Cystic Fibrosis · 2017 · 90 citations

Life Sciences, Genetics, Molecular Genetics +17

The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del<i>CFTR</i>variant

Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, I. Durieu et al. · European Respiratory Journal · 2023 · 85 citations

Medicine, Pharmacology, Pharmacotherapy +14

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Patrick A. Flume, Reta Fischer Biner, D.G. Downey et al. · The Lancet Respiratory Medicine · 2021 · 51 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon et al. · The Lancet Respiratory Medicine · 2024 · 47 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +12